Context: Mutations in the gene encoding Mediator complex subunit MED12 are dominant 50 drivers of uterine fibroids (UFs) in women of diverse racial and ethnic origins. Previously, we 51 showed that UF-linked mutations in MED12 disrupt its ability to activate Cyclin C-CDK8/19 in 52 Mediator. However, validation of Mediator kinase disruption in the clinically relevant setting 53 of MED12-mutant UFs is currently lacking.
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The authors declare that they have no conflicts of interest with the contents of this article. Introduction 8 findings suggest that MED12 mutations are drivers of fibrotic transformation. First, 160 predominant monoallelic expression of mutant MED12 has been observed in UF tumors, 161 indicative of a pathogenic requirement for a functionally altered MED12 allele 162 (16, 23, 27) . Second, directed expression of a MED12 mutant transgene (c. 131G>A; 163 p.G44D) in the uterine compartment of mice is sufficient to induce UF formation, 164 providing direct genetic proof of disease causality (33) . Nonetheless, the impact of UF-165 linked mutations on MED12 function and the molecular basis for their tumorigenic 166 potential remain to be clarified.
167
In this regard, we previously reported that UF-linked exon 1 and 2 mutations in 168 MED12 lead to disruption of Mediator-associated CDK activity, with significant 169 implications for global dysregulation of gene expression programs. Mechanistically, we 170 showed that these UF-linked mutations in MED12 disrupt its ability to bind directly to 171 CycC, an interaction necessary for MED12-mediated activation of CycC-dependent 172 CDK8/19 within Mediator (23, 34, 35) . These findings identified for the first time a common 173 molecular defect associated with UF-linked mutations in MED12 and further implicate 174 aberrant CDK8/19 activity in UF pathogenesis. Nonetheless, direct validation of Mediator 175 kinase disruption in the clinically relevant setting of MED12-mutant uterine fibroid 176 tumors has only very recently been reported from a restricted set of Caucasian (Finnish 9 from MED12 mutation-negative and MED12 mutation-positive UFs as well as adjacent 185 normal myometrium. We found that MED12 exon 2 mutations occur at high frequency 186 (54.1%) in Hispanic patients, suggesting that MED12 mutations are important drivers of UF 187 formation in this ethnic population. Moreover, we document that Mediator kinase activity 188 is indeed selectively and severely impaired in MED12-mutant UFs. Together, these findings 189 confirm in a clinically relevant setting that UF-linked mutations in MED12 disrupt Mediator- 
198
Sample histology was reviewed by a board certified gynecologic pathologist. In total, 219 199 uterine fibroid and 28 myometrium samples from 76 patients, including 57 Hispanic women, 9 10 AATGGCACTCTGGGATCGTG (reverse). The PCR products were purified with Gel Extraction Kit 210 (QIAGEN, Valencia, CA, USA) prior to Sanger sequencing (GENEWIZ, South Plainfield, NJ, USA).
211
The sequences were analyzed manually for the MED12 gene exon 2 somatic mutations. 
Results

262
MED12 is frequently mutated in UFs from Hispanic women of South Texas
264
In total, we sequenced 219 UFs from 76 patients, including 170 tumors from 57 Hispanic 265 women, for evidence of MED12 exon 2 mutations (Tables 1 and 2; Supplementary Tables 266 S1-S4). In addition, matched myometrial tissues available from 28 patients were also 267 included for sequence analysis (Tables S3 and S4 (Table 3 ). In addition,
272
among the 121 total MED12-mutant UFs, 10 carried a missense mutation in codon 36, 1 273 carried a missense mutation in codon 68, and 6 carried in-frame exonic deletions that 274 variously spanned 3-13 codons in length (Table 3) . Among the 92 UFs from Hispanic 275 patients, 8 harbored codon 36 mutations and 4 displayed in-frame exonic deletions. As 276 expected, no mutations were found in adjacent myometrium, confirming the somatic 277 nature of the UF mutations in MED12 ( Fig. 1; Fig. S1 ; Tables S3 and S4 ). All tumors 278 examined carried only one MED12 mutation, and all mutations were heterozygous in 279 nature, with the mutant allele predominantly expressed. Thus, cDNA sequencing revealed 280 that tumors harboring missense mutations and deletions internal to exon 2 expressed 281 both mutated and wild-type alleles, with the former generally more abundant than the 282 latter ( Fig. 1 ). Consistent with prior published findings, a significant correlation was 283 observed between MED12 mutation status and fibroid tumor size, with tumors carrying 284 the most frequent MED12 mutation (c.131G>A; p.G44D; 40/121 or 33% of total UFs) found 13 considered, a distinction not observed in previous studies. Beyond tumor size, no 288 correlations were observed between MED12 mutation status and either UF number or 289 location, nor were any relationships noted between MED12 mutation status and patient 290 age, BMI, or parity.
292
Identification of a minimal CycC-CDK8/19 binding and activation domain on MED12
293
Previously, we and others have shown that MED12 is an obligate activator of CycC-294 CDK8/19 in Mediator (34, 35) . Mechanistically, we showed that MED12 allosterically 295 activates both CDK8 and CDK19 through a direct interaction between MED12 and a 296 phylogenetically conserved surface groove on CycC (34, 35) . Importantly, we mapped the 
404
Further studies will be required to identify key substrates of Mediator kinases most 405 relevant to UF pathogenesis.
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Halder Supplemental Table S4 
.G44V A A A C A A G G T T T C A A T 53Fc cDNA c. 131G>T, p.G44V A A A C A A G T T T T C A A T T A A A A C A A G G T T T C A T A A A A C A A C G T T T C A A A A A C A A G G T T T C A A A A A A C A A A G T T T C A A A A C A A G G T T T C A A T A 44Fa genomic DNA wild type A A A C A A G G T T T C A
Supplemental Figure S1 A A A A C A A G G T T T C A
A 51Fa genomic DNA c. 131G>A, p.G44D G G A T G A A C T G A C G G C 104Fx genomic DNA c. 107T>G,
p.L36R A A A A C A A G G T T T C A
